NCT02687984View on ClinicalTrials.gov

PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Schizophrenia
Interventions
DRUG

RBP-7000

A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.

Trial Locations (2)

90502

Collaborative Neuroscience Network, Torrance

92845

Collaborative Neuroscience Network, LLC, Garden Grove

Sponsors

Lead Sponsor

Indivior Inc.
All Listed Sponsors
lead

Indivior Inc.

INDUSTRY

NCT02687984 - PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia | Biotech Hunter | Biotech Hunter